High ROIC Stocks
MDXG is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
MIMEDX GROUP INC (MDXG) Stock Price & Overview
NASDAQ:MDXG • US6024961012
Current stock price
3.43 USD
+0.08 (+2.39%)
At close:
3.3809 USD
-0.05 (-1.43%)
After Hours:
The current stock price of MDXG is 3.43 USD. Today MDXG is up by 2.39%. In the past month the price decreased by -12.94%. In the past year, price decreased by -50.36%.
MDXG Key Statistics
52-Week Range3.185 - 7.99
Current MDXG stock price positioned within its 52-week range.
1-Month Range3.185 - 4.1
Current MDXG stock price positioned within its 1-month range.
- Market Cap
- 509.595M
- P/E
- 8.37
- Fwd P/E
- 30.57
- EPS (TTM)
- 0.41
- Dividend Yield
- N/A
MDXG Stock Performance
Today
+2.39%
1 Week
+0.44%
1 Month
-12.94%
3 Months
-34.79%
Longer-term
6 Months -49.26%
1 Year -50.36%
2 Years -44.32%
3 Years -10.44%
5 Years -64.64%
10 Years N/A
MDXG Stock Chart
MDXG Stock Screens
MDXG currently appears in the following ChartMill screener lists.
High Free Cash Flow Stocks
MDXG is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
Revenue Growth Leaders
MDXG is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
Small Cap Growth Stocks
MDXG is part of our Small Cap Growth Stocks list, indicating it is a fast growing small cap stock.
MDXG Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MDXG. When comparing the yearly performance of all stocks, MDXG is a bad performer in the overall market: 93.37% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
MDXG Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to MDXG. MDXG has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MDXG Earnings
On February 25, 2026 MDXG reported an EPS of 0.1 and a revenue of 118.09M. The company beat EPS expectations (16.71% surprise) and beat revenue expectations (8.43% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$0.10
Revenue Reported118.095M
EPS Surprise 16.71%
Revenue Surprise 8.43%
MDXG Forecast & Estimates
12 analysts have analysed MDXG and the average price target is 9.86 USD. This implies a price increase of 187.46% is expected in the next year compared to the current price of 3.43.
For the next year, analysts expect an EPS growth of -72.63% and a revenue growth -15.29% for MDXG
Analysts
Analysts81.67
Price Target9.86 (187.46%)
EPS Next Y-72.63%
Revenue Next Year-15.29%
MDXG Groups
Sector & Classification
MDXG Financial Highlights
Over the last trailing twelve months MDXG reported a non-GAAP Earnings per Share(EPS) of 0.41. The EPS increased by 41.38% compared to the year before.
Income Statements
Revenue(TTM)418.63M
Net Income(TTM)48.58M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.6% | ||
| ROA | 14.18% | ||
| ROE | 18.94% | ||
| Debt/Equity | 0.06 |
Chartmill High Growth Momentum
EPS Q2Q%100%
Sales Q2Q%27.11%
EPS 1Y (TTM)41.38%
Revenue 1Y (TTM)19.99%
MDXG Ownership
Ownership
Inst Owners73.24%
Shares148.57M
Float145.09M
Ins Owners2.34%
Short Float %5.29%
Short Ratio7.29
MDXG Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDXG
Company Profile
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 808 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Company Info
IPO: 2007-08-20
MIMEDX GROUP INC
1775 W Oak Commons Court, Ne
Marietta GEORGIA 30062 US
CEO: Timothy R. Wright
Employees: 808
Phone: 17706519100
MIMEDX GROUP INC / MDXG FAQ
Can you describe the business of MIMEDX GROUP INC?
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 808 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Can you provide the latest stock price for MIMEDX GROUP INC?
The current stock price of MDXG is 3.43 USD. The price increased by 2.39% in the last trading session.
Does MIMEDX GROUP INC pay dividends?
MDXG does not pay a dividend.
What is the ChartMill rating of MIMEDX GROUP INC stock?
MDXG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is MIMEDX GROUP INC (MDXG) stock traded?
MDXG stock is listed on the Nasdaq exchange.
How is the valuation of MIMEDX GROUP INC (MDXG) based on its PE ratio?
The PE ratio for MIMEDX GROUP INC (MDXG) is 8.37. This is based on the reported non-GAAP earnings per share of 0.41 and the current share price of 3.43 USD.
What is MIMEDX GROUP INC worth?
MIMEDX GROUP INC (MDXG) has a market capitalization of 509.60M USD. This makes MDXG a Small Cap stock.